832、0.600。经Rcv2、VIF、FIT、AIC等检验,该模型具有良好的稳健性及预测能力。根据进入此模型的M66,M18,M2可知,影响嘧啶吗啉苯甲酰胺衍生物对Hedgehog信号通路抑制活性的主要因素是分子的二维结构特征CH3-、-CHf-、-NHg-、>N-和HO-等结构碎片。
逐渐增多的研究表明,人们生活中经常接触到的一些化学物质是导致乳腺癌发生的危险因素;同时一些研究证实,Hedgehog(Hh)信号通路在乳腺癌患者组织中存在异常激活,参与乳腺癌的发生、调节乳腺癌干细胞生物学特性、促进肿瘤组织血管新生和乳腺癌细胞侵袭转移等生物学过程。本文通过对化学物质与Hh信号通路在乳腺癌发生、发展研究的最新进展进行综述,为进一步阐述乳腺癌发病机制和乳腺癌的预防及控制提供科学线索。
Pancreatic cancer(PC) has been one of the deadliest of all cancers, with almost uniform lethality despite aggressive treatment. Recently, there have been important advances
in the molecular, pathological and biological understandingof pancreatic cancer. 很少 Even after the emergence of recent new targeted agents and the use of multiple therapeutic combinations, no treatment option is viable in patients with advanced GDC-0199细胞系 cancer. Developing novel strategies to target progression of PC is of intense interest. A small population of pancreatic cancer stem cells(CSCs) has been found to be resistant to chemotherapy and radiation therapy. CSCs are believed to be responsible for tumor initiation, progression and metastasis. The CSC research has recently achieved much progress in a variety of solid tumors, including pancreatic cancer to some extent. This leads to focus on understanding the role of pancreatic CSCs. The focus on CSCs may offer new targets for prevention and treatment of this deadly cancer. We review
the most salient developments in important areas of pancreatic CSCs. Here, we provide a review of current updates and new insights on the role of CSCs in pancreatic tumor progression with special emphasis on Dcl K1 and Lgr5, signaling pathways altered by CSCs, and the role of CSCs in prevention and treatment of PC.
近30年来大量的研究发现,Hedgehog信号通路不仅参与体内各种细胞的生存、增殖和分化等过程,在正常胚胎发育和器官形成中具有重要作用,同时,该通路的异常活化与多种肿瘤的形成与演进密切相关。针对Hedgehog信号通路的抗肿瘤研究已经成为一个热门的研究方向,将有可能发展出新的治疗手段。本文就此通路与肿瘤的关系及其在软骨肿瘤中的研究成果进行综述。
Patients
with pancreatic cancer have a poor prognosis with a median survival of 4-6 mo and a 5-year survival of less than 5%. Despite therapy with gemcitabine, patient survival does not exceed 6 mo, likely due high throughput screening compounds to natural resistance to gemcitabine. Therefore, it is hoped that more favorable results can be obtained by using guided immunotherapy against molecular targets. This review summarizes the new leading targeted therapies in pancreatic cancers, focusing on passive and specific immunotherapies. Passive immunotherapy may have a role for treatment in combination with radiochemotherapy, which otherwise destroys the immune system along with tumor cells. It includes mainly therapies targeting against kinases, including epidermal growth factor receptor, Ras/Raf/mitogenactivated protein kinase cascade, human epidermal growth factor receptor 2, insulin growth factor-1 receptor, phosphoinositide 3-kinase/Akt/m TOR and hepatocyte growth factor receptor.